405 related articles for article (PubMed ID: 33272955)
1. Overlapping central and peripheral nervous system syndromes in MOG antibody-associated disorders.
Rinaldi S; Davies A; Fehmi J; Beadnall HN; Wang J; Hardy TA; Barnett MH; Broadley SA; Waters P; Reddel SW; Irani SR; Brilot F; Dale RC; Ramanathan S;
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272955
[TBL] [Abstract][Full Text] [Related]
2. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management.
Ambrosius W; Michalak S; Kozubski W; Kalinowska A
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374173
[TBL] [Abstract][Full Text] [Related]
3. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination.
Ramanathan S; Mohammad S; Tantsis E; Nguyen TK; Merheb V; Fung VSC; White OB; Broadley S; Lechner-Scott J; Vucic S; Henderson APD; Barnett MH; Reddel SW; Brilot F; Dale RC;
J Neurol Neurosurg Psychiatry; 2018 Feb; 89(2):127-137. PubMed ID: 29142145
[TBL] [Abstract][Full Text] [Related]
4. E.U. paediatric MOG consortium consensus: Part 1 - Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Bruijstens AL; Lechner C; Flet-Berliac L; Deiva K; Neuteboom RF; Hemingway C; Wassmer E; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
Eur J Paediatr Neurol; 2020 Nov; 29():2-13. PubMed ID: 33162302
[TBL] [Abstract][Full Text] [Related]
5. Myelin oligodendrocyte glycoprotein antibody-associated disease: an immunopathological study.
Takai Y; Misu T; Kaneko K; Chihara N; Narikawa K; Tsuchida S; Nishida H; Komori T; Seki M; Komatsu T; Nakamagoe K; Ikeda T; Yoshida M; Takahashi T; Ono H; Nishiyama S; Kuroda H; Nakashima I; Suzuki H; Bradl M; Lassmann H; Fujihara K; Aoki M;
Brain; 2020 May; 143(5):1431-1446. PubMed ID: 32412053
[TBL] [Abstract][Full Text] [Related]
6. Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system.
Tanaka M; Tanaka K
J Neuroimmunol; 2014 May; 270(1-2):98-9. PubMed ID: 24703097
[TBL] [Abstract][Full Text] [Related]
7. Patterns and utility of myelin oligodendrocyte glycoprotein (MOG) antibody testing in cerebrospinal fluid.
Burton JM; Youn S; Al-Ani A; Costello F
J Neurol; 2024 May; 271(5):2662-2671. PubMed ID: 38366070
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of rituximab for relapse prevention in myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG)-associated disorders (MOGAD): A systematic review and meta-analysis.
Nepal G; Kharel S; Coghlan MA; Rayamajhi P; Ojha R
J Neuroimmunol; 2022 Mar; 364():577812. PubMed ID: 35063726
[TBL] [Abstract][Full Text] [Related]
9. E.U. paediatric MOG consortium consensus: Part 4 - Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Bruijstens AL; Breu M; Wendel EM; Wassmer E; Lim M; Neuteboom RF; Wickström R; ; Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostasy K
Eur J Paediatr Neurol; 2020 Nov; 29():32-40. PubMed ID: 33183945
[TBL] [Abstract][Full Text] [Related]
10. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
[TBL] [Abstract][Full Text] [Related]
11. The clinical spectrum of anti-MOG associated acquired demyelinating disorders: Three case-reports.
Bellinvia A; Pastò L; Razzolini L; Fratangelo R; Prestipino E; Fonderico M; Tudisco L; Amato MP
Mult Scler Relat Disord; 2019 Aug; 33():51-54. PubMed ID: 31152967
[TBL] [Abstract][Full Text] [Related]
12. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
Chen JJ; Bhatti MT
Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
[TBL] [Abstract][Full Text] [Related]
13. Case Report: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder Masquerading as Multiple Sclerosis: An Under-Recognized Entity?
Zheng Y; Cai MT; Li EC; Fang W; Shen CH; Zhang YX
Front Immunol; 2021; 12():671425. PubMed ID: 34220818
[TBL] [Abstract][Full Text] [Related]
14. MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis.
Vecchio D; Virgilio E; Naldi P; Comi C; Cantello R
Mult Scler Relat Disord; 2018 Apr; 21():9-10. PubMed ID: 29438836
[TBL] [Abstract][Full Text] [Related]
15. E.U. paediatric MOG consortium consensus: Part 2 - Neuroimaging features of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders.
Baumann M; Bartels F; Finke C; Adamsbaum C; Hacohen Y; Rostásy K;
Eur J Paediatr Neurol; 2020 Nov; 29():14-21. PubMed ID: 33158737
[TBL] [Abstract][Full Text] [Related]
16. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis.
Oliveira LM; Apóstolos-Pereira SL; Pitombeira MS; Bruel Torretta PH; Callegaro D; Sato DK
Mult Scler; 2019 Dec; 25(14):1907-1914. PubMed ID: 30417715
[TBL] [Abstract][Full Text] [Related]
17. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort.
Ketelslegers IA; Van Pelt DE; Bryde S; Neuteboom RF; Catsman-Berrevoets CE; Hamann D; Hintzen RQ
Mult Scler; 2015 Oct; 21(12):1513-20. PubMed ID: 25662345
[TBL] [Abstract][Full Text] [Related]
18. Relapsing optic neuritis and meningoencephalitis in a child: case report of delayed diagnosis of MOG-IgG syndrome.
Zhong X; Chang Y; Tan S; Wang J; Sun X; Wu A; Peng L; Lau AY; Kermode AG; Qiu W
BMC Neurol; 2019 May; 19(1):94. PubMed ID: 31072329
[TBL] [Abstract][Full Text] [Related]
19. Clinical and immunological differences between MOG associated disease and anti AQP4 antibody-positive neuromyelitis optica spectrum disorders: Blood-brain barrier breakdown and peripheral plasmablasts.
Tanaka S; Hashimoto B; Izaki S; Oji S; Fukaura H; Nomura K
Mult Scler Relat Disord; 2020 Jun; 41():102005. PubMed ID: 32114369
[TBL] [Abstract][Full Text] [Related]
20. MOG-IgG testing strategies in accordance with the 2023 MOGAD criteria: a clinical-laboratory assessment.
Risi M; Greco G; Masciocchi S; Rigoni E; Colombo E; Businaro P; Scaranzin S; Morandi C; Bisecco A; Bini P; Diamanti L; Gallo A; Franciotta D; Gastaldi M
J Neurol; 2024 May; 271(5):2840-2843. PubMed ID: 38280000
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
